Pro-Pharmaceuticals Announces Dosing of Cancer Patient with DAVANAT-R-/5-FU in a Phase II Clinical Trial at Hematology-Oncology Associates of Treasure Coast.
Linked as:
Extract
Pro-Pharmaceuticals Announces Dosing of Cancer Patient with DAVANAT-R-/5-FU in a Phase II Clinical Trial at Hematology-Oncology Associates of Treasure Coast.
NEWTON, Mass. -- Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds that enable the targeted delivery of chemotherapy drugs to cancer cells, today announced the d...
See the full content of this document
Sponsored links
